technology scouting at bayer healthcare
TRANSCRIPT
TECHNOLOGY SCOUTING (TS) –we serve your needs
Dr. Jörg KnäbleinTECHNOLOGY SCOUTINGBayer HealthCare Pharmaceuticals; Berlin, S107, 01, 117Phone: +49 30 468-1 6852; Fax: +49 30 468-9 6852 Mobile: +49 160 972 06850E-mail: [email protected]: http://www.bayer.com
Workshop Czech RepublicPharma TechTransfer 11th of October 2012
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
TECHNOLOGY SCOUTING (TS) – we serve your needs
ANIMAL MODELS ●Preamble ●Search criteriaBIOBANKING and BIOMARKER●Preamble●Search criteriaTRG CARDIOLOGY●Acute Care Research (ACS, PAOD, Ischemic Stroke, DIC, ALI/ARDS)●Heart Diseases (Heart Failure, Atrial Fibrillation, Cardioprotection) ●Kidney Diseases (Diabetic Nephropathy, CKD, Acute Renal Insufficiency)●Vascular Disease (Pulmonary Hypertension)●Hemoglobinopathies (Sickle Cell Disease, Beta-Thalassemia, Hemophilia A and B)TRG ONCOLOGY / GYNOGOLOGICAL THERAPIES●Cell cycle / Survival Signaling (Cell cycle inhibition, Induction of apoptosis)●Chromatin Modulation and OncoGenomics (Transcription and chromatin modulators)●Tumor Metabolism (Inhibition of tumor metabolism and Selective targeting)●Cancer Immune Therapy and Antibody Drug Conjugates (neutralize immunosuppression, selective killing)●Hyper-proliferative Diseases (Uterine fibroids, and Endometriosis / adenomyosis uteri)CORPORATE INFORMATION●Reasons to Partner with Bayer●Overview: Bayer HealthCare
Topics and keywords for external search performed by TECHNOLOGY SCOUTING for focused search in academia:
Animal Models
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
Animal models (transgenic, syngeneic, knock-out, knock-in, xenografts, orthotrop)As a research-based pharmaceutical company, Bayer Healthcare Pharmaceuticals is aware of the ethical issues inherent to research with animal models. All experiments performed at Bayer Healthcare Pharmaceuticals are in accordance with guidelines of the German and European codes for animal experiments. We are collaborating with providers and scientific institutes who are key opinion leaders in their field and employing best practice to establish animal models characterized by minimal burden, high predictability and a high level of feasibility.External search: in-licensing/scientific collaborations on disease-relevant & predictive animal models for
TRG ONCOLOGY / GYNECOLOGICAL THERAPIES (updated 06-2012)
1/2
☑
● Models of the following indications: gastric, prostate, head & neck, melanoma, colon, bladder, ovarian, triple-negative breast (TNB) cancer, including the aspects of metastasis, e.g. models of brain/bone metastasis due to lung, breast and prostate tumors
● Models refractory to clinically approved therapies (e.g. Tarceva-resistant lung CA, Herceptin-resistant mamma CA, Avastin-resistant/insensitive tumors, Taxane-resistant tumor models)
● Models addressing the topics “tumor metabolism” and “anti-tumor immune responses”● 3D-in-vitro technologies, Cell/cell & Cell/ECM interactions, “sprouting” or “microenvironment” for tumor
growth studies● Gynecological Indications: uterine fibroids, endometriosis / adenomyosis uteri; dysfunctional uterine
bleeding● Animal models for GT (rat, mouse, primate): uterine fibroids, endometriosis / adenomyosis, human
xenografts for uterine fibroids & endometriosis, pain in endometriosis, dysmenorrhea, dysfunctional bleeding
● GT Mechanisms: transgenic & K.O. animals targeting proteins related to proliferative, extra cellular matrix, angiogenic, inflammatory/painful or menorrhagic events in endometriosis or uterine fibroids
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
As a research-based pharmaceutical company, Bayer Healthcare Pharmaceuticals is aware of the ethical issues inherent to research with animal models. All experiments performed at Bayer Healthcare Pharmaceuticals are in accordance with guidelines of the German and European codes for animal experiments. We are collaborating with providers and scientific institutes who are key opinion leaders in their field and employing best practice to establish animal models characterized by minimal burden, high predictability and a high level of feasibility.External search: in-licensing/scientific collaborations on disease-relevant & predictive animal models for
Animal models (transgenic, syngeneic, knock-out, knock-in, xenografts, orthotrop)
2/2
●Short-term animal models e.g. innovative imaging techniques for PAOD and ischemic stroke●Animal models with respect to development state for thrombotic disorders mimicking high risk patients●Animal models with underlying cause Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS)●Animal models mirroring sec. pulmonary Hypertension (e.g. PH/COPD)●Animal models for on-line tracking of Heart Failure development and therapy success●Animal models mirroring Atrial Fibrillation (AF)●Animal models of acute and chronic kidney injury, diabetic nephropathy●Ischemic stroke (prevention) models●Bleeding models
TRG CARDIOLOGY (updated 06-2012)☑
Biobanking and Biomarker
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needsHuman specimen-based Research (Oncology / Gynecological Therapies, Cardiovascular)Two lines of pharmaceutical research build upon access to human specimens, target identification and validation, and biomarker validation and qualification. E. g. in oncology, comparing the expression profile of a diseased tissue with that of a normal adjacent sample might lead to novel ideas for a targeted therapy. Comparing the protein content of a tissue sample with a peripheral blood sample in ELISA measurements might lead to less invasive diagnostic possibilities, i. e. biomarker validation (there is much lower interest in techniques for identifying biomarkers).As a research-based pharmaceutical company, Bayer Healthcare Pharmaceuticals is aware of the ethical issues inherent to this kind of research and is collaborating with clinicians who are key opinion leaders in their field employing best practice (e. g., asking for IRB vote and patients' informed consent). A win-win situation exists where we are accepted as scientific research partner, e. g. offering access to analytical measurements for joint, peer-reviewed publications.Focus of external search is on scientific collaborations for
☑●the big five indications breast, colon, lung, ovarian, prostate (in particular the process of metastasis), as well as gastric,
head & neck, melanoma, bladder, and triple-negative breast (TNB) cancer ●refractory to targeted therapy (e. g. Tarceva-resistant lung CA, Herceptin-resistant mamma CA, Avastin-
resistent/insensitive tumors, Taxane-resistant tumor models)●Tissue from endometriosis / adenomyosis uteri patients and respective biomarkers
Oncology/Gynecological Therapies (updated 06-2012)
☑
●Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease (PAH, COPD), ACS,Kidney Failure, Peripheral Arterial Occlusion Disease (PAOD, different stages), ALI, ARDS, AKI
●Heart (cardiomyopathy of different NYHA classes); Atrial Fibrillation (AF)●Thrombotic disorders, Acute Lung Injury, ARDS, Acute Kidney Injury
Cardiovascular (updated 06-2012) ☑
Cardiology (updated 06-2012)
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
Bayer Healthcare Pharmaceuticals’ goal with its Cardiology business is to sustainable protect people‘s heart and bloodstream, because Cardiovascular Diseases have become a severe problem in our society. Early diagnosis and therapy of cardiovascular diseases plays a significant role – this is why our research concentrates on innovative approaches for several heart and vascular diseases as well as anti-coagulants.As a research-based pharmaceutical company, Bayer Healthcare Pharmaceuticals continues to prevent occlusion of blood vessels (thrombosis), thromboembolism (e.g. lung embolism) or dissolving clots (peripheral arterial occlusion) thereby focusing on novel treatment approaches with a balanced risk-benefit profile. Moreover, novel approaches in cardiovascular specialty indications (acute and intensive care) are of high interest to reduce the high unmet need in emergency rooms or intensive care units.Focus of external search is on proprietary (small and biological) molecules (e.g. inhibitors), innovative approaches, new mechanism-of-action, state-of-the-art in-vitro, in-vivo and ex-vivo pharmacology models, and biomarkers for
●Chronic treatment, high risk patients●No acute therapy●New biomarkers
Acute Coronary Syndromes (ACS) anticoagulation, antiplatelets
☑CARDIOLOGY – Acute Care Research (ACS, PAOD, Ischemic Stroke, DIC, ALI/ARDS)
●Novel therapeutic approaches●Predictive animal models e.g. innovative imaging techniques●New biomarkers
Peripheral Arterial Occlusive Disease (PAOD), Ischemic Stroke (IS) prevention, and Critical Limb Ischemia (CLI)
●Novel therapeutic approaches●Predictive animal models with respect to development state●Identifying disease-stage specific biomarkers
Acute/Intensive Care e.g. Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS), Acute Kidney Injury (AKI), Disseminated Intravascular Coagulation (DIC)
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
Bayer Healthcare Pharmaceuticals’ goal with its Cardiology business is to sustainably protect people‘s heart and bloodstream, because Cardiovascular Diseases have become a severe problem in our society. Early diagnosis and therapy of cardiovascular diseases plays a significant role – this is why our research concentrates on innovative approaches for several heart and vascular diseases as well as anti-coagulants.As a research-based pharmaceutical company, Bayer Healthcare Pharmaceuticals continues to improve and protect heart function in patients with heart failure and other heart diseases as well as secondary forms of pulmonary hypertension. Focus of external search is on proprietary (small and biological) molecules (e.g. inhibitors), innovative approaches, new mechanism-of-action, state-of-the-art in-vitro, in-vivo and ex-vivo pharmacology models, and biomarkers for
●Novel therapeutic approaches for anti-remodeling, function improvement and diastolic HF●Predictive animal models for remodeling processes and diastolic HF●Sex and gender-specific models for heart diseases●New biomarkers monitoring therapeutic success
Heart Failure (HF)
☑CARDIOLOGY –Heart Diseases (Heart Failure, Atrial Fibrillation, Cardioprotection)
AFib
Sinus rhythm●Novel therapeutic approaches for rate and rhythm control●Predictive animal models
Atrial Fibrillation (AF)
●Novel therapeutic approaches for prophylaxis of cardiac injuries●Predictive animal models for prim. and sec. prophylaxis●New biomarkers (patient risk stratification for MACE)
Cardioprotection (ischemia/reperfusion)
AFib
Sinusrhyth
m
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
Bayer Healthcare Pharmaceuticals’ goal with its Cardiology business is to sustainably protect people‘s heart and bloodstream, because Cardiovascular Diseases have become a severe problem in our society. Early diagnosis and therapy of cardiovascular diseases plays a significant role – this is why our research concentrates on innovative approaches for several heart and vascular diseases as well as anti-coagulants.As a research-based pharmaceutical company, Bayer Healthcare Pharmaceuticals continues to improve and protect renal function in patients with acute and chronic kidney dysfunction and insufficiency. Focus of external search is on proprietary (small and biological) molecules (e.g. inhibitors), innovative approaches, new mechanism-of-action, state-of-the-art in-vitro, in-vivo and ex-vivo pharmacology models, and biomarkers for
●Novel therapeutic approaches to protect diabetic patients from developing and worsening of DN●Predictive animal models●Biomarkers for early monitoring of therapeutic success
Diabetic Nephropathy (DN)
☑CARDIOLOGY –Kidney Diseases (Diabetic Nephropathy, CKD, Acute Renal Insufficiency)
AFib
Sinus rhythm
●Novel therapeutic approaches ●Predictive animal models●Biomarkers for early monitoring of therapeutic success
Chronic Kidney Disease (CKD) progression
●Novel therapeutic approaches ●Predictive animal models●Biomarkers for early monitoring of therapeutic success
Acute Renal Insufficiency
●Novel therapeutic approaches ●Predictive animal models and biomarkers
Cardiovascular Diseases associated with CKD
●Novel therapeutic approaches ●Predictive animal models●Biomarkers for early monitoring of therapeutic success
Ischemia- or hypertension- induced CKD
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
Bayer Healthcare Pharmaceuticals’ goal with its Cardiology business is to sustainably protect people‘s heart, lungs and bloodstream, because Cardiovascular Diseases have become a severe problem in our society. Early diagnosis and therapy of cardiovascular diseases plays a significant role – this is why our research concentrates on innovative approaches for several heart, lung and vascular diseases as well as anti-coagulants.As a research-based pharmaceutical company, Bayer Healthcare Pharmaceuticals continues to improve and protect heart function in patients with heart failure and other heart diseases as well as primary & secondary forms of pulmonary hypertension. Focus of external search is on proprietary (small and biological) molecules (e.g. inhibitors), innovative approaches, new mechanism-of-action, state-of-the-art in-vitro, in-vivo and ex-vivo pharmacology models, and biomarkers for
●PAH despite recent therapeutic advances remains a deadly disease●NO-deficiency can underlie treatment failure of PDE5-inh.●New therapeutic approaches are of interest (target ideas)●New biomarkers
Pulmonary Arterial Hypertension (PAH)
☑CARDIOLOGY – Vascular Disease (Pulmonary Hypertension)
AFib
Sinus rhythm
Secondary Pulmonary Hypertension (e.g. assoc. with lung diseases)
●Current Bayer portfolio offers upside potential towards art. hypertension●Current focus: resistant art. Hypertension (rHT)●Stratification of patients with rHT
Arterial Hypertension
●Novel therapeutic approaches for sec. PH●Focus on the interaction of PH and underlying (lung) disease●Predictive animal models for sec. PH●Relevance of PH for underlying disease●Subgroup analysis of pat. with secondary PH-forms incl. underlying diseases
Chronic forms of peripheral vascular diseases
●Novel therapeutic approaches●Predictive animal models e.g. innovative imaging techniques●New biomarkers
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
Bayer Healthcare Pharmaceuticals’ goal with its Cardiology business is to sustainably protect people‘s heart, lungs and bloodstream, because Cardiovascular Diseases have become a severe problem in our society. Early diagnosis and therapy of cardiovascular diseases plays a significant role – this is why our research concentrates on innovative approaches for several heart, lung and vascular diseases as well as anti-coagulants.Leverage hematology / cardiology expertise, particularly in disease complication modeling, with hemophilia core knowledge to enter new indications in hemoglobinopathies.Focus of external search is on proprietary (small and biological) molecules (e.g. inhibitors), innovative approaches, new mechanism-of-action, state-of-the-art in-vitro, in-vivo and ex-vivo pharmacology models, and biomarkers for
☑CARDIOLOGY – Hemoglobinopathies (Sickle Cell Disease, Beta-Thalassemia, Hemophilia A and B)
Bayer’s cardiology compounds in development●Novel antithrombotics in thrombosis indications e.g. anticoagulant rivaroxaban (Xarelto®)●sGC – modulator franchise: frontrunner riociguat in phase III studies in pulmonary hypertension
Bayer seeks to pursue hemoglobinopathies through collaborative partnerships leveraging partner’s scientific know-how and Bayer’s expertise.
Oncology (updated 06-2012)
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
The vision of the oncology research at Bayer Healthcare Pharmaceuticals is to improve the lives of patients affected by cancer. Our pipeline offers therapies for both solid tumors (e.g. prostate, liver, colon, breast, kidney, lung, gastric and pancreatic cancer) and benign hyper-proliferative diseases (e.g. uterine fibroids, endometriosis). It includes innovative therapeutic strategies for the inhibition of tumor growth and cell proliferation using small molecule compounds (e.g. kinase inhibitors) and biological compounds (e.g. antibody drug conjugates (ADC), and function blocking antibodies.Beyond our own research efforts, we cooperate in multiple partnerships with health care professionals, universities, academic research centers, other pharmaceutical companies, and innovative biotechnology organizations. Our solid relationships with the scientific community foster an open exchange of ideas and information and help to expand our vision of treatment. Focus of external search is on proprietary new targets and tools, small molecules (e.g. kinase inhibitors), proteins (e.g. antibodies), plasmids and cell lines, in-vitro technologies for functional analyses and animal models in the fields of
☑ ONCOLOGY / GYNECOLOGICAL THERAPIES (innovative therapies for solid tumors)
●Cell cycle inhibition●Tumor cell selective induction of apoptosis or other forms of cell death
Cell cycle / Survival Signaling
●Transcription and chromatin modulators●Specific antagonism/suppression of steroid receptors
Chromatin Modulation and OncoGenomics
●Inhibition of tumor metabolism ●Selective targeting of tumor-specific metabolic dependencies
Tumor Metabolism
●by counteracting immunosuppressive activities (e.g. immune checkpoint inhibition)●by actively triggering immune response (e.g. BiTE)●by selective killing of tumor cells using antibody drug conjugates (ADCs)
Cancer Immune Therapy and Antibody Drug Conjugates (ADCs)
Disease-relevant & predictive animal models for● all types of cancer● tumor metabolism● triggering immune responses
3D-in-vitro technologies● Cell/cell and Cell/ECM interactions
●Uterine fibroids ●Endometriosis / adenomyosis uteri
Hyper-proliferative Diseases
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
☑ ONCOLOGY / GYNECOLOGICAL THERAPIES (innovative therapies for solid tumors)
Chromatin Modulation
Cancer Stem Cells
Cancer Immuno-therapy
Tumor Metabolism & Hypoxia
Cell Cycle & Survival Signaling
Antibody-Drug Conjugates
Cancer Genomics
Bayer Oncology Research Areas
Page * Global Innovation Sourcing • – February 2012
Bayer HealthCare Pharmaceuticals Research Focus
Cardiology
Gynecological Therapy
Oncology●Pulmonary Hypertension /
Heart Failure●Thrombosis / Acute Coronary
Syndrome●Cardiorenal Syndrome (CRS)
● Endometriosis- Uterine Fibroids
●Cell Cycle / Survival Signaling ●Immunotherapy / Antibody-
Drug Conjugates●Tumor Metabolism / Hypoxia●Chromatin Modulation /
OncoGenomics
Hematology●Anemia and other blood diseases●LCM long acting factor VIII
Common Mechanism Research & Other Areas●Leveraging the full potential of development compounds●Ophthalmology●Inflammation●LCM Fertility Control / Menopause-Management ●Magnetic Resonance and Computed Tomography Contrast Media Research
TECHNOLOGY SCOUTING (TS)– presentation available upon request
Dr. Jörg Knäblein TECHNOLOGY SCOUTINGBayer Healthcare PharmaceuticalsPhone: +49 30 4681 6852 Mobile: +49 160 972 06850E-mail: [email protected]
Reasons to Partner with Bayer
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
Page * • Global Innovation Sourcing • – February 2012
BHC Global Innovation Sourcing
We Talk Science,
and LivePartnerships!
Understand Business,
Page * • Global Innovation Sourcing – February 2012
Our Strengths
We want to share our experience with external innovative partners
●Proven track record in identifying and optimizing innovative SMOL leads
●One of the world‘s largest compound library (∼ 3 million cpds)●Ultra-high-throughput compound screening platform in 1536-well
format●HT protein optimization platform●Human antibody / antibody-drug conjugate technology●Protein analytics and clinical manufacturing●Excellent cardiology pharmacology with long experience●Strong oncology expertise with focus on `first in class´ molecules●Well established oncology network
Page * • Global Innovation Sourcing • – February 2012
Reasons to partner with Bayer
●We want to add real value to the compound or therapeutic area●We are flexible regarding collaboration terms and models●We leave our partners room to develop and prosper●We put emphasis on strong alliance management●We have excellent research and manufacturing capabilities●We are responsive and committed during the entire partnering●We compensate adequately
Bayer HealthCare has a proven track record of successful partnerships
Page * • Global Innovation Sourcing • – February 2012
Bayer – Already A SelectedPartner of Choice For Many
You are welcome to join us!
Discovery/Technologies
Development/Distribution
Bayer Pharma‘s „From Targets To Novel Drugs“ Initiative
Overview: Bayer HealthCare
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TS – we serve your needs
Page * • Global Innovation Sourcing – February 2012
Bayer HealthCare’s Top-Selling Productsof Today
Sales FY2010, currency-adjusted, € mio.
Page * • Global Innovation Sourcing – February 2012
Bayer: Science For A Better LifeSales 2010
Bayer CropScience
Bayer MaterialScience Bayer HealthCare (BHC)€17 billion€10.1 billion
€6.8 billion
28.9%
19.5%
54.2%
Thank you!
Page * Bayer HealthCare Overview – February 2012
Forward-Looking Statements This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
TECHNOLOGY SCOUTING (TS) –we serve your needs
Dr. Jörg KnäbleinTECHNOLOGY SCOUTING, Global Innovation SourcingBayer HealthCare Pharmaceuticals; Berlin, S107, 01, 117Phone: +49 30 468-1 6852; Fax: +49 30 468-9 6852 Mobile: +49 160 972 06850E-mail: [email protected]: http://www.bayerpharma.de
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
Scope:
Source, identify & evaluate valuable Tech Offers / ASSETS (compounds, biomarker, animal models, cells, biospecimens, technologies, co-operations, projects) from academic groups world wide
Clients:
Internal customers are from all indications & all sites: GTR, LGO, ER groups, BUs, but also GD; plus special requests from GPTs asking for specific (external) support
Source:
External key sources are academic research institutes, universities, TTOs, bioregions, databases, newsletters, publications, meetings, site-visits, conferences and – personal communication
TS is complementary to other Innovation Sourcing activities → value add is focus on “terra incognita” (unpublished)
TS knows internal needs due to close interaction with BHC community – utilized sources come from personal contacts
●Conferences / Active Role●Networking / Personal Contacts●Reach Out / Efficient Trips●Educational Advertising /
Trustful Scientist●Leverage Internal Resources
TS addresses “Innovation Gap”: maturity, communication, and confidence
TS
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
Unique Selling Proposition of TS is access to ASSETS notyet published – enabled by global network of personal contacts
Focused search in continuously extended network.Ask for specific technologies at appropriate partners.Follow-up with experts for other possible sources.
Focused Scouting: specific requests at personal contacts yield maximum ASSETS
Trust & scientific acceptance → ASSETS from invisible “terra incognita”
t
ASSETS
visible
invisible “terra incognita”
Evolution of scouting strategy
receiving offers
passive
screen databases
active
ask TTOs
proactive
specific requestdirectly @experts
focused
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
Bayer BD&L
DDIUSA
NBV
… BUs
CANADA
JAPAN
… ROW
BHC
●Research institutes ●Universities / TTOs
Sources/Offers
“multiplier“what‘s needed
TS communication / interfaces essential to get ASSETS: “Tell sources what BHC needs – and BHC what sources have”
GDDTechnologyScouting
push
pull
push
pull
TS presentation●Summary of what BHC needs
External: Team Rooms (PIx)●“Target-specific” repositories
Internal:
●ER groups, BUs●GPTs,
individuals
BHC Needs
what‘s needed & what we have
“identifier”
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
Team Rooms (PIx)
precise & tight criteria
Filter One:
ASSETS
selected byBU/Functions
Filter Two:
WIP
acceptable conditions(e.g. resources)& sponsor
Filter Three:
TS uses precise, continuously updated, and very tight selection criteria to identify ASSETS: all indications, all categories, all sites
in-house@Bayer
Animal ModelsBiomarker/ -BanksCell LinesCompoundsProjectsTechnologies
ONC WH DI CV
Rigorous filtering (e.g. 98% attrition @Filter One) yields in valuable Tech Offers → ASSETS
> 10
.000
Tec
h O
ffers
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
Page * Global Innovation Sourcing • – February 2012
Bayer HealthCare Pharmaceuticals - Research Focus
Cardiology
Gynecological Therapy
Oncology●Pulmonary Hypertension /
Heart Failure●Thrombosis / Acute Coronary
Syndrome●Cardiorenal Syndrome (CRS)
● Endometriosis- Uterine Fibroids
●Cell Cycle / Survival Signaling ●Immunotherapy / Antibody-
Drug Conjugates●Tumor Metabolism / Hypoxia●Chromatin Modulation /
OncoGenomics
Hematology●Anemia and other blood diseases●LCM long acting factor VIII
Common Mechanism Research & Other Areas●Leveraging the full potential of development compounds●Ophthalmology●Inflammation●LCM Fertility Control / Menopause-Management ●Magnetic Resonance and Computed Tomography Contrast Media Research
TECHNOLOGY SCOUTING (TS)– presentation available upon request
Dr. Jörg Knäblein TECHNOLOGY SCOUTINGBayer Healthcare PharmaceuticalsPhone: +49 30 4681 6852 Mobile: +49 160 972 06850E-mail: [email protected]
TechTransfer Initiative
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TECHNOLOGY SCOUTING (TS) – presentation available upon request
Pharma perspective on TechTransfer in Germany
TECHNOLOGY TRANSFER – Meeting in Berlin in August 2011
Attendies●Manfred Horst (MSD)●Jörg Knäblein (Bayer)●Marcus Kostka (Boehringer Ingelheim)●Ralph Kray (Johns Hopkins Business School)●Lucks (Novartis)●Hüls (MerckSerono)●Burkhard Fugmann (BIG)
Best practice sharing - TTO and PharmaCommon understanding of optimization potential●No harmonized clear dataset for technology offers – highly diverse●Technology transfer professional: skills, edjucational background, motivation
and overview on research activities●No existing central portal to access all existing technology offers ●PVA´s not acting as central business partner for Pharma●Optimization of training for TTO professionals (Curriculum)
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TECHNOLOGY SCOUTING (TS) – presentation available upon request
Standardization of TechOffers (content / data / info / format)
TECHNOLOGY TRANSFER – proposal for standardized TechOffers
Prerequisite – all data and information non-confidential 1. Summary of mode of action, target or new pathway/mechanism in the context of relevant indication2. Summary of the most important biology/pharmacology data including the status of the in vivo efficacy profile 3. Information about type of opportunity – NCE/NBE vs method/assay vs technology (drug delivery, formulation etc)4. If NCE/NBE overview on compound profiling status (DMPK, CMC, Tox, Gen Pharm)5. IP – status and owner of patent applications6. Further information – citation of relevant publications, patents, or links
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TECHNOLOGY SCOUTING (TS) – presentation available upon request
Standardization of TechOffers (content / data / info / format)
TECHNOLOGY TRANSFER – proposal for standardized TechOffers
Additional points to consider for TechTransfer – at a later stage 1. Business model a) License model for Foreground IP (created during collaboration): university to own with NERF (non-exclusive royalty free) license to sponsor + option for exclusivity to sponsor OR all to sponsor with license? b) License model for Background IP: milestones, option for exclusivity?2. Payment for development activities: effort (man hours, consumables etc) or fixed package? Milestone based?3. Insight into cost structure (separating actual cost from overhead)
Points for discussion:1. Proposal of technology transfer portal (communication platform) with standardized and up to date opportunities 2. Proposal on harmonizing technology transfer by using the existing PVA´s per state with respective professional skills and education3. Improvement of skills by continues training of technology transfer professions at academia and institutes4. Start dialogue with academic partners on TT optimization on both ends
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TECHNOLOGY SCOUTING (TS) – presentation available upon request
Standardization of TechTransfer (content / data / info / format)
TECHNOLOGY TRANSFER – additional thoughts from pharma colleagues
Create market place the place to look to get away from “accidental” identification of opportunities
Harmonization is also the “management of expectations” at both ends
Skill setBesides the “jack of all trades device” for BAT IIa we wish the following:
Non dogmatic, pragmatic personality (tough to train, but very important)
Excellent negotiation skills (Harvard Business School training or equivalent)●Sound understanding of pharmaceutical development processes●Understanding of work in a highly regulated environment (GLP, GMP, GCP etc.)●Sound understanding of IP principles including “Employee Inventions Act”●Basics of “Contracting” & Legal language
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TECHNOLOGY SCOUTING (TS) – presentation available upon request
Standardization of TechTransfer (content / data / info / format)
TECHNOLOGY TRANSFER – current status
Meeting held with TT managers from academia 21st Sep 2011
These "areas of improvement„ (worked out from a pharma perspective) were presented at a meeting with academic patent commercialization agencies (4. Treffen der Arbeitsgruppe Technologietransfer) on Wednesday, 21st of September 2011 in Mannheim. This initiative to improve Tech Transfer between academia and industry was very much appreciated by all participants.
Joint meeting with managers from academia and industry 17th of Nov 2011
Due to the success of the Mannheim meeting and the importance of this topic, attendees asked to organize another exchange forum for academia and industry to intensify and improve Tech Transfer .This meeting was held on the 17th of at Bayer in Düsseldorf. Besides colleagues from Bayer, BI, Merck, and Novartis, essentially ALL German patent commercialization agencies attended. This was judged as indicator for the importance of tis initiative.
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TECHNOLOGY SCOUTING (TS) – presentation available upon request
Standardization of TechTransfer (content / data / info / format)
TECHNOLOGY TRANSFER – next steps
Next meeting with EuKTS planned for 7th Mar 2012 in Mnunich
As an important next step we have planned discussions with BMBF (Federal Ministry of Education and Research) to ensure a specific pharma TechTransfer curriculum and its region wide establishment. Also it is planned to closely interact with the European Knowledge Society (EuKTS) to harmonize all efforts and bring the TechTransfer initiative on a European level.
A meeting with industry representatives from the TechTransfer initiative and academic representatives from the German patent commercialization agencies will be held on 7th of March in Munich. Here we will discuss a joint strategy with representatives from EuKTS.
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TECHNOLOGY SCOUTING (TS) – presentation available upon request
TT Curriculum for TT offices and companies
TECHNOLOGY TRANSFER – proposal for TT Curriculum (1/2)
A. Innovation1. Discovery and invention process2. Product design and innovation3. Managing the innovation process in a company
kindly provided by Johns Hopkins
B. Intellectual Property1. Concept of intellectual property and different type of IP2. Patenting, what constitutes something that can be patented3. Patent landscaping4. Patent claims and patenting strategy
C. Market Research1. Market research (purpose and types)2. Most common techniques of market research (focus groups, user surveys, conjoint analysis, potential customer surveys)3. Estimating market size and market growth
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
TECHNOLOGY SCOUTING (TS) – presentation available upon request
TT Curriculum for TT offices and companies
TECHNOLOGY TRANSFER – proposal for TT Curriculum (2/2)
D. Go-to-Market Strategies1. Types of go to market strategies (start up, merger/acquisition, license)2. Valuation of the IP3. Financing the go-to-market strategy (sources of financing and costs)
E. Business Planning1. Concept of the business model2. Writing the business plan: key elements3. The Elevator Pitch4. Governance and ownership structure of the company
Dr. Jörg Knäblein TECHNOLOGY SCOUTING (TS), GDD Global Innovation Sourcing# * +49 30 468 1 6852, [email protected]
Global Innovation SourcingPartnering Activities @ Global Drug
Discovery
Page * • Global Innovation Sourcing – February 2012
Page * • Global Innovation Sourcing – February 2012
Bayer HealthCareDivisions
Page * Global Innovation Sourcing • – February 2012
●Hematology ●Biologics Research &
Development●Science Hub US
●Oncology●Women’s
Healthcare●Diagnostic Imaging
●Cardiology●Oncology●Biologics Research &
Development●Animal Health Research
●GDD InnovationCenter China
●Bayer TsinghuaCenter for InnovativeDrug Discovery
●Investment in R&D 2010: € 1.8 billion●Investment in R&D of 2010 total net sales:
16.1%●R&D Employees: 6,200 (2010)
Berkeley / San Francisco
Berlin
Wuppertal / Cologne
/Monheim
Beijing
Bayer HealthCareResearch at a Glance
Page * Global Innovation Sourcing – February 2012
Our R&D Pipeline Provides a Balanced Mix of NME and LCM Opportunities
New MolecularEntities (NME)Life CycleManagement (LCM)
Status as of October 2011Table provides a selection of major pipeline projects of Bayer HealthCare
Phase I (10)CancerPI3K Inhibitor (BAY 80-6946)CancerCDK-Inhibitor (BAY 1000394)CancerHIF1a – Inhibitor (BAY 97-2243)CancerBAY 94-9343 (Mesothelin-ADC)AnemiaBAY 85-3934 (HIF-PH)Sympt. Uterine FibroidsBAY 1002670 (S-PRAnt)Diagnostic ImagingPET-TracerMCIBAY 94-9172 (Florbetaben)HemophiliaBAY 94-9027 (peg rFVIII)HemophiliaBAY 86-6150 (rFVIIa)
Phase II (11)Ovarian/Peritoneal CancerSorafenibAdditional IndicationsSorafenibLung InfectionCipro inhaleGram-negative PneumoniaAmikacin inhale
CHF BAY 94-8862 (MR Antagonist)Pulmonary HypertensionRiociguat (sGC Stimulator)CancerRegorafenibCancerBAY 86-9766 (MEK-Inhibitor)Bone Mets Breast CancerAlpharadinAtopic DermatitisMapracorat (SEGRA)EDBAY 60-4552/Vardenafil
Phase III (19)CRVOVEGF Trap-EyeMyopic CNVVEGF Trap-EyeDMEVEGF Trap-EyePAHRiociguat (sGC Stimulator)CTEPHRiociguat (sGC Stimulator)CRCRegorafenibGISTRegorafenibAlzheimer PET ImagingBAY 94-9172 (Florbetaben)Submental fat removalATX-101
VTE TreatmentRivaroxabanACSRivaroxabanNSCLCSorafenibThyroid CancerSorafenibBreast CancerSorafenibMultiple SclerosisAlemtuzumabContraception LCS (ULD LNG)Contraception FC Patch LowMRI LCM GadovistVV Atrophy Vaginorm
Page * • Global Innovation Sourcing – February 2012
Strong BHC Clinical Pipeline
Status as of July 2011Table provides a selection of major pipeline projects of Bayer HealthCare
Phase III (19)NSCLC / SorafenibThyroid Cancer / SorafenibBreast Cancer / SorafenibCRC / RegorafenibGIST / RegorafenibVTE Treatment / RivaroxabanACS / RivaroxabanPAH / Riociguat (sGC Stimulator)CTEPH / Riociguat (sGC Stimulator)Myopic CNV / VEGF Trap-EyeDME / VEGF Trap-EyeCRVO / VEGF Trap-EyeContraception / LCS (ULD LNG)Contraception / FC Patch LowVV Atrophy / FSD / VaginormMRI LCM / GadovistMultiple Sclerosis / AlemtuzumabSubmental fat removal / ATX-101
Phase II (12)Cancer / RegorafenibCancer / MEK-InhibitorBone Mets Breast Cancer / AlpharadinOvarian / Peritoneal Cancer / SorafenibCRC / SorafenibAdditional Indications / SorafenibCHF / MR AntagonistPH / Riociguat (sGC Stimulator)ED / BAY 60-4552/VardenafilAtopic Dermatitis / Mapracorat (SEGRA)Lung Infection / Cipro DPIGram-negative Pneumonia / Amikacin inhale
Phase I (9)Cancer / PI3K InhibitorCancer / CDK InhibitorCancer / HIF1a InhibitorAnemia / HIF-PHHemophilia / BAY 94-9027Hemophilia / BAY 86-6150Sympt. Uterine Fibroids / S-PRAntMCI / FlorbetabenDiagnostic Imaging / PET-Tracer
Oncology Cardiology/HematologyWomen’s HealthcareDiagnostic ImagingOphthalmologyOthers
Page * • Global Innovation Sourcing – February 2012
Status as of July 2011Table provides a selection of major pipeline projects of Bayer HealthCare
Phase III (19)NSCLC / SorafenibThyroid Cancer / SorafenibBreast Cancer / SorafenibCRC / RegorafenibGIST / RegorafenibVTE Treatment / RivaroxabanACS / RivaroxabanPAH / Riociguat (sGC Stimulator)CTEPH / Riociguat (sGC Stimulator)Myopic CNV / VEGF Trap-EyeDME / VEGF Trap-EyeCRVO / VEGF Trap-EyeContraception / LCS (ULD LNG)Contraception / FC Patch LowVV Atrophy / FSD / VaginormMRI LCM / GadovistMultiple Sclerosis / AlemtuzumabSubmental fat removal / ATX-101
Phase II (12)Cancer / RegorafenibCancer / MEK-InhibitorBone Mets Breast Cancer / AlpharadinOvarian / Peritoneal Cancer / SorafenibCRC / SorafenibAdditional Indications / SorafenibCHF / MR AntagonistPH / Riociguat (sGC Stimulator)ED / BAY 60-4552/VardenafilAtopic Dermatitis / Mapracorat (SEGRA)Lung Infection / Cipro DPIGram-neg. Pneumonia / Amikacin inhale
Phase I (9)Cancer / PI3K InhibitorCancer / CDK InhibitorCancer / HIF1a InhibitorAnemia / HIF-PHHemophilia / BAY 94-9027Hemophilia / BAY 86-6150Sympt. Uterine Fibroids / S-PRAntMCI / FlorbetabenDiagnostic Imaging / PET-Tracer
Oncology Cardiology/HematologyWomen’s HealthcareDiagnostic ImagingOphthalmologyOthers
More Than 40% From In-Licensing Or Together With External Partners
Page * • Global Innovation Sourcing • – February 2012
The Global Innovation Sourcing Team is your partner atBHC when it comes to discussions about early assets andtechnologies, for licensing as well as for out-partneringactivities.
Companies harbor only a small portionof the biomedical knowledge
●Even with a budget of >1.5 billion €, BHC Pharmaceuticals R&Donly represents <1% of the annual spending on biomedical R&Dglobally
●Closer relationship to partners in academia and biotech neededto make better use of the existing knowledge and to address themajor challenges in biomedical R&D
●Research collaborations with academic, small biotech firms orlarge pharmaceutical corporations are an integral element of ourinnovation strategy
●Collaborations in all phases of the value chain – from research to development and production to marketing.
Page * • Global Innovation Sourcing • – February 2012
Partnering Organization Works AlongThe Value Chain
Clinical development Ph
IIIPh II Ph I
Pre-Clin. Dev.
Lead discoveryTD LOLDResearch
Driven by scientific concepts and data Driven by clinical PoC data
Innovation Sourcing
Business development
●Access to projects and new sources of innovation through partnerships and licenses
●Innovative / flexible partnership models to find mutually beneficial solution
●Responsibility for licensing, out-partnering of early assets, collaborative research
Page * • Global Innovation Sourcing • – February 2012
Feedback from Our Academic Partners
Prof. Multhaup, Free University of Berlin, Germany:“We have experienced an excellent support by Bayer HealthCare Scientists and have had encouraging discussions.”
Prof. Wang, Moores UCSD Cancer Center, La Jolla, USA:“There are two advantages in the G4T program. The first being the speed with which the grant is funded. The second being the potential of further collaboration in the future to advance the common research interests between my laboratory andBayer AG.”
Prof. Otmar D. Wiestler, Scientific Director of DKFZ, Heidelberg, Germany:“Bayer HealthCare is an ideal partner for German Cancer Research Center because it is committed to pursue innovative therapeutic concepts and invest in high-risk ideas. We experience Bayer HealthCare as a reliable, highly competent partner with an open mindset. Our alliance clearly generates a win-win situation and can serve as a model for public-private partnerships in the biomedical field.”
Page * • Global Innovation Sourcing – February 2012
Feedback from Our Biotech Partners
Jens Hennecke, Ph.D., SVP, Business Development, Micromet“Our collaboration with Bayer is built on trust and a shared desire to utilize the skills and strengths of both organizations to develop a new therapy for prostate cancer. We view Bayer to be an ideal partner on account of its expertise in oncology, shared conviction in the promise of our technology, excellent collaborative spirit and ability to aggressively advance a product through development and onto the market. We are very pleased with the rapid progress achieved so far under this collaboration since its inception in 2009 and look forward to continuing to work together to ultimately treat cancer patients with BAY2010112 / MT112.”
Paul Hastings, President and CEO, OncoMed Pharmaceuticals“We have greatly enjoyed working with Bayer on our Wnt Pathway partnership, which was forged in June 2010. The collaborative spirit of the interactions has resulted in significant R&D progress, including our first antibody in the pathway (OMP-18R5) advancing to clinical testing earlier this year, and significant progress on our 2nd biologic program and small molecule discovery efforts. This is a great example of how biotech and pharma companies can bring the best of their respective talents to advance innovation.”
Page * • Global Innovation Sourcing – February 2012
●Global strategic alliance signed in June 2010●Focus on the discovery, development and
commercialization of novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway
●Bayer with the option to exclusively license antibody and protein therapeutic product candidates at any point up to the completion of Phase I testing
●Bayer and OncoMed share technology and know-how to discover and develop small molecule inhibitors of the Wnt pathway
●FDA accepted OncoMed‘s IND filing for a monoclonal Anti-Frizzled antibody (OMP-18R5 ) in April 2011
Some Examples in More Detail … OncoMed / Tumor Stem Cells
Wnt PathwayWnt Pathway
Biologics
Small Molecules
Transcription on
Page * • Global Innovation Sourcing • – February 2012
Some Examples … German Cancer Research Center Alliance
●First agreement signed in 2007, collaboration extended for another 3 yearsin 2011
●German Cancer Research Center (DKFZ) as the largest biomedical oncology research center in Europe
●Collaboration along the entire drug discovery and development value chain●Novel risk and reward sharing approach to collaborate with joint financing
(1 million Euro / year / partner) and project selection (currently >9 joint projects)●Ideal partnership due to high strategic fit and complementary competencies
Bench Bedside
Page * • Global Innovation Sourcing – February 2012
Some Examples …Tsinghua University Beijing
●Comprehensive collaboration agreement signed in 2009●The 1st strategic partnership with long-term commitment to discover new
targets/molecules in China●Tsinghua University is the No.1 university in China with the fastest growing life science
disciplines, led by world renowned structural biologist, Prof. Yigong Shi●Bayer-Tsinghua Joint Research Center of Innovative Drug Discovery (BTC) founded
Letter of Intent Signing, November 2008
BTC Inauguration Ceremony, June 2009
Page * • Global Innovation Sourcing • – February 2012
Some Examples …Grants4Targets Initiative
Preclinical
Submission
Clinical
LeadGeneration
TargetDiscovery
LeadOptimi-zation
http://www.grants4targets.com
Background●Numerous targets exist, but are “invisible” for us●The knowledge outside > inside Idea●Join forces with academia and biotech start ups to translate innovative targets
into drugs●Provision of grants to evaluate and validate novel targets – “Grants 4 targets”Approach●Easily accessible Internet site and submission tool●Low bureaucratic burden for both partners ●Clear communication on “needs” – what are we looking for?●Fast processing of requests
Page * • Global Innovation Sourcing • – February 2012
Some Examples … The Innovative Medicines Initiative (IMI)
●Biggest Public Private Partnership in Life Science; joint budget of €2 billion
●Focus on efficacy in 5 disease areas, safety, knowledge management andeducation & training
●IMI projects address key pre-competitive bottlenecks identified by Pharma
●Public funding goes exclusively to non-pharma partners like academia,small and medium enterprises, patient organizations and regulators
Projects
Page * • Global Innovation Sourcing – February 2012
Conclusion
●Bayer HealthCare is committed to innovation●Partnerships are key for being world-class in research & development ●Complementary skills and expertise offer excellent basis for future collaborations●We look forward to establishing joint projects – to find and evaluate
new targets and define new treatment options for the benefit of patients
External innovation is a key component in our R&D strategy
Page * • Global Innovation Sourcing – February 2012
Global Partnering with Academiaand Industry Along the Value Chain
Clinical/POC
Grants4Targets (Global)Online crowd sourcing; over 70 grants for new target research provided
OncoMedCorporate partnership on cancer stem cell therapies
ArdeaCorporate licensing of MEK inhibitors for cancer
Innovative Medicines InitiativePublic private partnership between European Commission & Pharma
German Cancer Center (DKFZ)Strategic partnership with joint financing; > 9 projects running Tsinghua University
10 collaborative projects across therapeutic areas
SingaporeMultiple programs for diagnosis: treatment of Asian specific cancer
Pre-clinical
Lead Generation/Optimization
Target Discovery
Page * • Global Innovation Sourcing – February 2012
Small Molecule CandidateGeneration Platform
Structural Biology,ComputationalChemistry
PharmacophoreInformatics,Property Prediction
Medicinal Chemistry,Automated Synthesisand Purification
Compound Collection,High-Throughput andHigh-Content Screening
●Generation of innovative small molecule lead structures using ultra-high-throughput screening of a ca. 3 million compound library in 1536-well format, supported by structural biology, fragment based technologies, etc.
●Optimization of leads to development compounds with high clinical success rate, origin of marketed drugs like Nexavar® and Xarelto®
●Close collaboration with Global Biologics on drug-antibody conjugates
Target Discovery
Compound Screening
Lead Generation
Lead Optimization
Preclinical Development
Clinic Phase I
Page * • Global Innovation Sourcing – February 2012
GDD-Global Biologics R&D
Marketed
Post-PoC
Research and Pre-clinical
Disease areas
Core capabilities
mAbs
ADCs
Engineered CFs
Fab
antigenIgG
Toxophore
VEGF Trap-Eye KG-PFAlemtuzumab
Biologics Pipeline
●Coagulation factor (CF) engineering
●Human antibody technology●HTP protein optimization●Antibody drug conjugates, incl.
analyticsand clinical manufacturing
●Oncology●Hematology●Cardiology●Gynecology●Ophthalmology
Page * • Global Innovation Sourcing – February 2012
Common Mechanism Research Platform
Target Discovery
Compound Screening
Lead Generation
Lead Optimization
Preclinical Development
Clinic Phase I
●Search for new indications for clinical development candidates using bioinformatic pathway analysis, data mining, phenotypic in vitro assays and in vivo models
●Inflammation platform to explore development of compounds across multiple indications to identify an optimal path forward
●Identification of new therapeutics for age-related macular degeneration
Bioinformaticsplatform, data mining(Phylosopher)
Phenotypic in vitro Models
in vivoPharmacology
Page * • Global Innovation Sourcing • – February 2012
●Addressing key pathomechanisms and novel treatment paradigms with SMOL and monoclonal antibodies●In the top group in areas like antibody-drug-conjugates, cell cycle regulation and survival signaling●Strong interest in areas like tumor metabolism, hypoxia, chromatin modulation, oncogenomics, cancer stem cells and cancer immunotherapy●Broad network of partners in academia and biotech
Bayer Oncology Research
Page * • Global Innovation Sourcing – February 2012
●Over 20 years experience with cardiovascular pharmacology and the identification and optimization of innovative compounds such as Adalat®, Xarelto® and riociguat●Focused on heart diseases (heart failure, atrial fibrillation), vascular diseases (pulmonary hypertension) and acute care (thrombosis, acute coronary syndrome, ischemic stroke)●State-of-the-art in vivo pharmacology with disease-mirroring animal models for CV indications in8 different species from mouse to dog. Clinical methods are used for the evaluation of compound efficacies which can then easily be translated into clinical studies●Broad network of KOLs and academic institutions in all focus disease areas
Bayer Cardiology Research
Page * • Global Innovation Sourcing – February 2012
BHC Global Innovation Sourcing
Understand
We Talk
and Live
Science
BusinessPartnerships
Page * Bayer HealthCare Overview – February 2012
Drug research Preclinical
Clinical trials
Evaluation/Approval
Phase IV studies
Probability of success from research to market approval: <1%
Source: based on PhRMA Profile Pharmaceutical Industry 2010
Years
0 2 4 6 8 10
12
14
16
18
(up to2 years)
(more than2 years)
10,000Test compounds
<250Test compounds
<5 Test compounds
Lab and animalexperiments
1 drug ap- proved byhealthauthorities
€ >1 billion
Phase I: 20-100 healthy volunteersPhase II: 100-500 patients ➔
safety, dosing
Phase III: 1,000-10,000 patients ➔
efficacy, adverse events
Page * Bayer HealthCare Overview • – February 2012
Improving R&D Efficiency and Maximizingthe Value of Transformational Late-Stage Pharmaceutical Pipeline Assets
●Establish Xarelto® (rivaroxaban) as an idealanticoagulant with the potential to redefine the market
●Demonstrate Nexavar®’s potential as a pan-tumor drugand a building block of Bayer’s global oncology franchise
●Transform hemophilia market by developinga long-acting Kogenate®
●Establish a new paradigm in the treatment of age-related macular degeneration with VEGF Trap-Eye
Thank you!
Page * Bayer HealthCare Overview – February 2012
Page * Bayer HealthCare Overview – February 2012
Forward-Looking Statements This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.